&lt;p&gt;Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study&lt;/p&gt;

Zhang, Kun; Ma, Xiuwei; Gao, Hongjun; Wang, Hong; Qin, Haifeng; Yang, Shaoxing; Liu, Xiaoqing

doi:10.2147/cmar.s246000

Cited by 37 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, univariate analysis showed significantly longer PFS in patients without EGFR mutation than in patients with the mutation. However, consistent with previous studies ( 12 , 13 , 30 ), cox regression analysis showed both EGFR status and previous EGFR target therapy were not independent risk factors for PFS in patients receiving anlotinib. EGFR-TKIs are standard first-line treatment for NSCLC patients with EGFR mutations.…”

Section: Discussionsupporting

confidence: 87%

“…Zhang et al. also reported brain metastases had no influence on PFS of NSCLC patients treated with anlotinib alone ( 13 ). However, in line with wu et al.…”

Section: Discussionmentioning

confidence: 99%

“…In another study of 52 NSCLC patients receiving anlotinib as third- or later-line treatment, Zhang et al. found median PFS and OS to be 4.5 months and 9 months, respectively, with relatively longer survival rates in patients with ECOG PS 0–1 and patients without liver metastasis ( 13 ). In contrast to these findings, Shao et al.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Xiong

Qin

Xin³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

AimsCombination of anti-angiogenesis therapy and immunotherapy has showed synergistic effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.MethodsPathologically confirmed NSCLC patients (stage IIIB-IV) receiving anlotinib between November 2018 and February 2020 were enrolled for retrospective analysis. The outcomes and safety of overall patients were evaluated, and the efficacies of anlotinib plus immunotherapy and anlotinib alone was compared. The primary endpoint was progression-free survival (PFS).ResultsA total of 80 patients (median age: 62 years, range: 29-86 years) were included. Overall median PFS was 4.3 months (95% confidence interval (CI): 2.7-5.9 months). In univariate analysis, patients without EGFR mutation, previous EGFR target therapy, and brain metastasis had significantly longer PFS. Cox regression analysis showed that only brain metastasis was an independent predictor of PFS. The median PFS of patients receiving anlotinib plus immunotherapy was slightly longer than that of patients receiving anlotinib alone (4.2 vs 3.1 months); however, the difference was not statistically significant. A tendency of longer median PFS was observed in patients with adenocarcinoma, EGFR wild type, stage IV, no liver metastasis, former smoker, ≥2 previous treatment lines, no previous VEGF or EGFR target therapies in anlotinib plus immunotherapy group. Treatments with anlotinib alone or anlotinib plus immunotherapy were well tolerable. The most common adverse events were fatigue, decreased hemoglobin count, hypertension, hand-foot syndrome, oral mucositis and hoarseness.ConclusionAnlotinib is well tolerable and effective in advanced NSCLC patients. Brain metastasis is an independent predictor of PFS in NSCLC patients receiving anlotinib. Future prospective studies with larger sample size and extended follow-up are needed to confirm the clinical benefit in NSCLC patients treated with anlotinib combined with immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 87%

“…Zhang et al. also reported brain metastases had no influence on PFS of NSCLC patients treated with anlotinib alone ( 13 ). However, in line with wu et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Xiong

Qin

Xin³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, the PFS bene t of the combination was observed in the subgroups with or without previous antiangiogenic therapy, although the upper limit of the 95% CI exceeded 1. These ndings are consistent with those in earlier studies, which showed that previous antiangiogenic therapy had no in uence on PFS and OS of ≥ third-line anlotinib treatment in aNSCLC (Han et al 2018;Shao et al 2019;Zhang et al 2020).…”

Section: Discussionsupporting

confidence: 92%

The Real-World Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer

Wang

Feng

Cheng

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world.Methods: Patients with aNSCLC receiving anlotinib were enrolled in two cohorts (treatment-naive and previously treated). The endpoints included progression-free survival (PFS), overall survival (OS) and anlotinib-related adverse events (ar-AEs).Results: 203 patients accrued in the study. In the treatment-naïve cohort (n=80), the PFS was 7.4 (95% confidence interval [CI], 4.1-10.7) and OS was 10.8 (95% CI, 5.8-15.8) months of monotherapy group (immature survival for combination group). In previously treated cohort (n=123), The PFS was 8.0 months (95% CI, 6.1-9.9) in the combination group and 4.3 months (95% CI, 2.1-6.6) in the monotherapy group (hazard ratio [HR], 0.49; 95% CI, 0.29-0.83; p=0.007), respectively. The OS was 18.5 months (95% CI, 10.5- to 26.6) in the combination group and 7.8 months (95% CI, 7.1-8.4) in the monotherapy group (HR, 0.38; 95% CI, 0.22-0.66; p=0.001), respectively. The ar-AEs of grade ≥3 in the monotherapy and the combination groups were hypertension (9.0% and 8.7%), fatigue (8.1% and 7.6%), hand-foot syndrome (8.1% and 6.5%), diarrhea (5.4% and 8.7%), proteinuria (5.4% and 5.4%), and mucositis oral (6.3% and 8.7%).Conclusion: In aNSCLC, anlotinib monotherapy has a promising efficacy in the first-line setting. It may be an option for those who are ineligible for chemotherapy; anlotinib combination therapy in a ≥ second-line setting showed manageable toxicities and encouraging efficacy, indicating a good application prospect.Trial registration: This study was retrospectively registered with ISRCTN Registry (ID ISRCTN35543977) on January 26th, 2021 and Chinese Clinical Trial Register (ChiCTR2000032265) on April 4th, 2020.

show abstract

“…The incidence of adverse events recorded in both groups was low and similar to those reported in the literature [25,[40][41][42][43][44][45][46]. In this study, the proportion of patients rechecking ECG, thyroid function and urine routine was small.…”

Section: Discussionsupporting

confidence: 86%

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Suo¹,

Sun²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective The purpose of this study was to initially investigate whether previous antiangiogenic therapy (bevacizumab and endostar) affect the efficacy of anlotinib in patients with lung cancer (LC). Methods We retrospectively collected the clinical data of LC patients treated with anlotinib. They were divided into two groups, namely group A (anlotinib after failure of previous antiangiogenic drugs and group B (no prior use of antiangiogenic drugs). Use propensity score matching (PSM) to control the confounding factors between the groups.Results A total of 160 patients were included in the analysis. The median OS in group A and group B was 11.8 months vs. 16.1 months (P=0.120), and the median PFS was 3.1 months, 4.7 months, respectively (P=0.009). The ORR of the two groups was 9.6% vs. 10.4% (P=0.874), and the DCR was 71.1 % vs. 80.5% (P=0.165).After PSM (n=46), baseline characteristics were equitably comparable between the two groups. It was found that the median OS of the two groups was 14.6 months vs. 16.2 months (P=0.320), and the median PFS was 3.5 months vs. 4.5 months (P=0.040). The ORR of the two groups were 13.0%, 10.9% (P=0.748), and the DCR were 78.3%, 82.6% (P=0.599), respectively. These results provided further evidence that although PFS of group A was relatively shorter than that of group B, it may not affect patients’ OS.Conclusions Previous antiangiogenesis treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient’s ORR and OS.

show abstract

<p>Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study</p>

Cited by 37 publications

References 32 publications

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

The Real-World Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Contact Info

Product

Resources

About